Marker Therapeutics is trading 5.26% up now at $1.60, aligned with stronger biotechnology sentiment after XBI gained 2.06% and broader risk appetite improved.
- Shares rose 1.33% during the August 25, 2026 regular session.
- No new company-specific announcement was identified for August 25.
- Recent gains also followed positive sector momentum from major oncology-trial developments, though no direct Marker Therapeutics catalyst was confirmed.